The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines to patients before they clear the traditional efficacy bar for authorization, Prasad said Tuesday.Newly installed at the agency, Vinay Prasad has committed to giving rare disease patients rapid access to “products that are even small steps forward” during his time as director of the FDA’s Center for Biologics Evaluation and Research.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
-0.055(2.97%) |
Mkt cap ! $2.293B | |||
| Open | High | Low | Value | Volume |
| $1.84 | $1.86 | $1.77 | $7.241M | 4.018M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 25472 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |